(0.05%) 5 102.48 points
(0.22%) 38 322 points
(0.06%) 15 938 points
(-1.31%) $82.75
(6.34%) $2.05
(-0.02%) $2 346.80
(-0.35%) $27.44
(3.84%) $957.55
(-0.18%) $0.933
(-0.31%) $10.99
(-0.51%) $0.796
(1.70%) $93.44
1.72% ¥ 3 855.00
Live Chart Being Loaded With Signals
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients...
Stats | |
---|---|
Dzisiejszy wolumen | 48 200.00 |
Średni wolumen | 31 521.00 |
Kapitalizacja rynkowa | 108.35B |
EPS | ¥0 ( 2024-04-25 ) |
Last Dividend | ¥50.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 26.32 |
ATR14 | ¥5.18 (0.13%) |
Wolumen Korelacja
Torii Pharmaceutical Co., Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Torii Pharmaceutical Co., Korelacja - Waluta/Towar
Torii Pharmaceutical Co., Finanse
Annual | 2023 |
Przychody: | ¥54.64B |
Zysk brutto: | ¥24.57B (44.97 %) |
EPS: | ¥146.57 |
FY | 2023 |
Przychody: | ¥54.64B |
Zysk brutto: | ¥24.57B (44.97 %) |
EPS: | ¥146.57 |
FY | 2022 |
Przychody: | ¥48.89B |
Zysk brutto: | ¥23.38B (47.81 %) |
EPS: | ¥140.38 |
FY | 2021 |
Przychody: | ¥46.99B |
Zysk brutto: | ¥24.34B (51.80 %) |
EPS: | ¥32.16 |
Financial Reports:
No articles found.
Torii Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥76.00 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.00 | 2001-03-27 |
Last Dividend | ¥50.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 47 | -- |
Total Paid Out | ¥907.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.09 | -- |
Div. Sustainability Score | 7.39 | |
Div.Growth Potential Score | 3.44 | |
Div. Directional Score | 5.41 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
4097.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3302.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2378.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
9308.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8038.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7283.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6533.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
5805.T | Ex Dividend Junior | 2023-09-28 | Sporadic | 0 | 0.00% | |
4548.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3771.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0939 | 1.500 | 8.12 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0398 | 1.200 | 8.67 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0444 | 1.500 | -0.618 | -0.927 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.50 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.20 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.280 | 1.500 | 9.56 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 32.66 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 32.66 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.448 | 1.000 | 5.86 | 5.86 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.122 | 1.000 | 9.56 | 9.56 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.423 | 0.800 | -0.511 | -0.409 | [0.5 - 2] |
Total Score | 7.39 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.50 | 1.000 | 8.03 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0444 | 2.50 | -0.397 | -0.927 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 32.66 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 32.66 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.448 | 1.500 | -0.349 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0163 | 1.000 | -2.09 | 0 | [0.1 - 0.5] |
Total Score | 3.44 |
Torii Pharmaceutical Co.,
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej